評論
打印
The first several weeks following her ketamine regimen were "the only time I can say I have felt normal" in 15 years, she says. "It's like you have 50 pounds on your shoulders, and the ketamine takes 40 pounds off."
曼寧說，接受氯胺酮治療的前幾周是15年來“我唯一感覺正常的一段時間。就好像你肩膀上有50磅的重物，氯胺酮能減掉40磅。”
She's now back in Maine, and the depression has returned.
現(xiàn)在，她回到緬因州，抑郁情緒也隨之返回。
Her current Medicare insurance won't cover ketamine. She lives on $1,300 a month in disability income. "Knowing it is there and I can't have it is beyond frustrating," she says.
她目前的醫(yī)療保險不能支付氯胺酮的費用，她每月靠1300美元的殘障收入維持生活。“知道有治療的方法，但我卻無法進行治療，那種心情難以言表，”她說。
Ketamine is considered a "dirty" drug by scientists—it affects so many pathways and systems in the brain at the same time that it's hard to single out the exact reason it works in the patients it does help.
科學家們認為氯胺酮是一種“骯臟”的藥物，它同時影響大腦中的許多通路和系統(tǒng)，因此很難找出它對那些治療有效的患者發(fā)揮作用的確切原因。
That's one reason researchers continue to look for better versions of the drug. Another, of course, is that new versions are patentable.
這是研究人員繼續(xù)尋找更好的藥物的一個原因，另一個原因當然是新藥物可以獲得專利。
Should Johnson & Johnson's esketamine hit the market, the ketamine pioneers and their research institutions stand to benefit.
如果強生公司的艾氯胺酮進入市場，那么使用氯胺酮的先驅者和他們的研究機構將從中受益。
Yale's Krystal, NIH's Zarate, and Sinai's Charney, all of whom are on the patent on Charney's wall, will collect royalties based on the drug's sales.
耶魯大學的科瑞斯，美國國家衛(wèi)生研究院的薩拉特和西奈山伊坎學院的查尼，他們的名字都列在查尼辦公室那面墻上所掛的專利證書之中，他們將根據(jù)藥物的銷售情況收取專利權稅。
J&J hasn't said anything about potential pricing, but there's every reason to believe the biggest breakthrough in depression treatment since Prozac will be expensive.
強生公司沒有對定價問題做出任何說明，但有充分的理由相信，自百憂解以來，在治療抑郁癥方面獲得最大突破的藥物將非常昂貴。
Concerns about the side effects of ketamine-style drugs linger. Some patients taking esketamine have reported experiencing disassociation symptoms.
人們對氯胺酮類藥物副作用的擔憂仍然存在。一些使用艾氯胺酮的患者報告出現(xiàn)了分離癥狀。
Johnson & Johnson calls the effects manageable and says they cropped up within an hour of the treatment, a period in which a person on the drug would likely be kept in the doctor's office for monitoring.
強生公司稱這些影響是可以控制的，它們會在開始治療的一小時內突然出現(xiàn)，在這段時間內，用藥患者可能留在醫(yī)生的辦公室里接受監(jiān)控。
Some patients also experienced modest spikes in blood pressure within the first 75 minutes. Nasal-spray dosing brings other issues.
某些患者在最初的75分鐘內還會出現(xiàn)輕微的血壓飆升，鼻腔噴霧劑給藥還會帶來其他問題。
The Black Dog Institute in Australia and the University of New South Wales in Sydney, which teamed up to study a nasal-spray form of ketamine, published their findings last March in the Journal of Psychopharmacology.
聯(lián)合研究鼻腔噴霧劑式氯胺酮的澳大利亞黑狗研究所和悉尼新南威爾士大學，在3月份的《精神藥理學期刊》上發(fā)表了他們的研究結果。
The researchers found that absorption rates were variable among patients. J&J says its own studies with esketamine contradict these findings.
研究人員發(fā)現(xiàn)，患者對藥物的吸收率存在差異。強生表示，他們對艾氯胺酮進行的研究與這些研究結果相矛盾。
